ANALIZADOR AUTOMATIZADO DE HEMOGLOBINA GLICOSILADA HLC-723®G8 TOSOH - COFEPRIS Registration 165E2019 SSA
Access comprehensive regulatory information for ANALIZADOR AUTOMATIZADO DE HEMOGLOBINA GLICOSILADA HLC-723®G8 TOSOH (AUTOMATED GLYCOSYLATED HEMOGLOBIN ANALYZER HLC-723®G8 TOSOH) in the Mexico medical device market through Pure Global AI's free database. This Clase I medical device is registered under COFEPRIS analysis ID 165E2019 SSA and manufactured by SOLUCIÓN INTEGRAL A SUS NECESIDADES REGULATORIAS, S.A. DE C.V.. The device was registered on February 01, 2019.
This page provides complete registration details including product type (I. MEDICAL EQUIPMENT), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.
EL HLC-723®G8 ESTÁ DESTINADO AL USO DIAGNÓSTICO IN VITRO PARA LA DETERMINACIÓN DEL PORCENTAJE CUANTITATIVO DE HEMOGLOBINA A1C (HBA1C) EN MUESTRAS DE SANGRE TOTAL, EN EL TRATAMIENTO CLÍNICO DE LA DIABETES PARA EVALUAR LA EFICACIA A LARGO PLAZO DEL CONTROL
HLC-723®G8 IS INTENDED FOR IN VITRO DIAGNOSTIC USE FOR THE DETERMINATION OF THE QUANTITATIVE PERCENTAGE OF HEMOGLOBIN A1C (HBA1C) IN WHOLE BLOOD SAMPLES, IN THE CLINICAL MANAGEMENT OF DIABETES TO EVALUATE THE LONG-TERM EFFICACY OF CONTROL